白雲山(00874.HK)擬斥8,900萬人幣認購混改二期投資基金份額
白雲山(00874.HK)(600332.SH)公佈,計劃出資8,900萬元人民幣認購認購廣州國資混改二期股權投資基金合夥企業(有限合夥)有限合夥份額,佔份額21.8673%。
混改二期基金計劃總規模爲4.07億元人民幣,主要圍繞廣州市混改項目;廣州汽車製造、石化能源、裝備製造等傳統支出產業機制創新、混合改革、優化升級;新一代信息技術、人工智能、生物醫藥產業與新能源、新材料戰略新興產業等領域進行投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.